Krystal Biotech (KRYS) Change in Account Payables (2016 - 2026)

Krystal Biotech has reported Change in Account Payables for 11 years, with the latest figure at $3.1 million in Q2 2026.

• Change in Account Payables for Q2 2026 came in at $3.1 million, down 25.85% year-over-year; the trailing twelve-month figure through Jun 2026 was -$124000.0 (down 102.74% YoY), and the FY2025 annual result was $826000.0, down 18.3% from the prior year.
• Change in Account Payables climbed to $3.1 million in Q2 2026, from $1.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.1 million in Q2 2025 and troughed at -$4.0 million in Q3 2025.
• A 5-year average of $253388.9 and a median of $99000.0 in 2023 frame the typical range for Change in Account Payables.
• The widest annual swing landed in 2024, when Change in Account Payables jumped 579.44%; it then plunged 4517.58% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$938000.0 in 2022, then jumped by 76.33% to -$222000.0 in 2023, then tumbled by 166.22% to -$591000.0 in 2024, then surged by 69.04% to -$183000.0 in 2025, then surged by 1770.49% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $3.1 million in Q2 2026, $1.0 million in Q1 2026, and -$183000.0 in Q4 2025.